GUTS Stock Overview
A metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Fractyl Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.39 |
| 52 Week High | US$14.50 |
| 52 Week Low | US$1.74 |
| Beta | 0 |
| 11 Month Change | -49.36% |
| 3 Month Change | -66.15% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -81.40% |
Recent News & Updates
Shareholder Returns
| GUTS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 34.3% | 1.9% | 4.0% |
| 1Y | n/a | 9.3% | 24.9% |
Return vs Industry: Insufficient data to determine how GUTS performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how GUTS performed against the US Market.
Price Volatility
| GUTS volatility | |
|---|---|
| GUTS Average Weekly Movement | 14.5% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: GUTS's share price has been volatile over the past 3 months.
Volatility Over Time: GUTS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 112 | Harith Rajagopalan | fractyl.com |
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.
Fractyl Health, Inc. Fundamentals Summary
| GUTS fundamental statistics | |
|---|---|
| Market cap | US$112.63m |
| Earnings (TTM) | -US$65.88m |
| Revenue (TTM) | US$119.00k |
962.6x
P/S Ratio-1.7x
P/E RatioIs GUTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUTS income statement (TTM) | |
|---|---|
| Revenue | US$119.00k |
| Cost of Revenue | US$70.00k |
| Gross Profit | US$49.00k |
| Other Expenses | US$65.93m |
| Earnings | -US$65.88m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.37 |
| Gross Margin | 41.18% |
| Net Profit Margin | -55,357.98% |
| Debt/Equity Ratio | 40.1% |
How did GUTS perform over the long term?
See historical performance and comparison